about
Assessment of quality of life in people living with HIV in Georgia.Mortality and causes of death among HIV-infected individuals in the country of Georgia: 1989-2012.Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia.The cascade of care in the Eastern European country of Georgia.Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia.Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of GeorgiaCharacteristics of HIV-infected women and factors associated with HCV seropositivity in the Republic of Georgia.IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1.The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia.High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatmentMismatch between physicians and family members views on communications about patients with chronic incurable diseases receiving care in critical and intensive care settings in Georgia: a quantitative observational surveyINCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA.Evaluation of multiple measures of antiretroviral adherence in the Eastern European country of Georgia.Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program.Progress Toward Achieving the UNAIDS 90-90-90 Goals in HIV Care From Diagnosis to Durable Viral Suppression in the Country of Georgia.Significant Improvements Are Needed in HIV Care Continuum to Meet 90-90-90 Targets in Georgia.Expansion of CD3/CD16/CD56 positive NKT cells in HIV/AIDS: the pilot study.Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPANational Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.Distinct drug resistance profile of HIV-1 subtype A strain circulating in Georgia.Cascade of care among HIV patients diagnosed in 2013 in Georgia: Risk factors for late diagnosis and attrition from HIV careEstimating HIV incidence in eastern European country of Georgia: 2010-2012.Prevalence of hepatitis B and C among HIV positive patients in Georgia and its associated risk factors.HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.Characterization of HIV-1 subtypes and drug resistance mutations among individuals infected with HIV in Georgia.Late presentation of HIV infection in the country of Georgia: 2012-2015.Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.HIV care in Central and Eastern Europe: How close are we to the target?Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populationsThe Attitudes, Needs, and Requirements at End of Life in the Republic of Georgia (Comparative Analysis of Groups of Patients With Cancer and Elders)Epidemiology of human immunodeficiency virus (HIV) drug resistance in HIV patients with virologic failure of first-line therapy in the country of GeorgiaUptake of HCV treatment in HIV/HCV coinfected patients across europe in the era of direct-acting antiviralsPersistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in GeorgiaImpact of hepatitis C virus antibody positivity on mortality and causes of death in people living with HIV in Georgia
P50
Q33652865-0A50E1C5-6F3E-4EFC-80A1-8552194371B2Q33713778-849C5810-A18C-4E86-8E58-FCBA9E825C84Q33914820-864D8628-BC24-4F53-851C-344E71CD3B1BQ34691650-DE1BC1E6-52F0-42C1-A3C0-C71158C63A12Q34730686-75256004-7120-48AF-8066-90BA908415AFQ35029529-B552CD0E-D96A-4A70-8633-E700BB2AD183Q35158311-60717D11-17D1-409A-87A7-6FE699C15B0AQ36012993-2892D454-86D2-46D9-8FC2-3DD5A4C2BC0AQ36538481-F707E469-1F5A-431A-A888-8813DD724701Q36676315-EA05930F-B6CD-406C-8785-C72A15276499Q37119353-341C2935-28CE-4AA6-8A3A-AE651437206AQ37420784-F0934148-7BE3-45E8-8E3D-805D4398CCB8Q37697607-1C9BBE61-9D9A-4625-8159-5EF8960FBDADQ38930180-A54C0EC5-2E19-4679-9B82-2C2045BEF948Q39041375-78A9C369-DE23-462E-A62B-69A20E2EBF58Q39388841-27C40CE9-1075-4413-BC4C-B768DE74C2D3Q40012416-B918DD0E-49F6-4473-917A-D15BAB4F3E59Q40063363-ADB8D755-CFDB-435A-AABA-04CB9971B053Q40496679-701CF225-0F8C-4309-900B-7A1339A426E5Q41065508-5CD93E44-08D2-4B52-8642-B0092F84DB43Q41835756-5269FB17-8151-449F-A79A-62DA3BAB6B03Q42222083-06C6FE28-8C4F-4B9A-8B3B-375CD62DE628Q42608204-E353B1B9-C734-4756-9457-4E84DD8B062FQ42756232-9A8C977A-3E07-4624-9359-328593E08782Q42985158-89BE7C33-A615-4E0F-8372-FD82E14A8C41Q43879996-C24EC58D-95A5-444C-AB30-1F8386E3F28DQ45781456-1179B262-96C3-4307-9C3B-075AD58A2995Q52597020-2B9F8935-269B-444C-B000-5E6E527A4A14Q52650613-69F9724F-9329-46ED-B618-361D81597955Q57023680-BA61F8A7-560D-48AE-8407-63A3655CC7C2Q57142488-E2393112-AAC3-4372-AFAF-3C2187A97DDFQ59358688-5D833A33-598A-4FC3-9D7B-6FD091D4F89EQ63363866-6413B99D-278D-4E75-B410-CFAC6341AF85Q63729599-5A8583FD-20D0-4169-A0CD-F8162B05AC2AQ63729611-8033FB24-186A-4EB8-8CF0-4B50A26E23FEQ90313366-1E605B93-D7D8-495F-8B5D-2FB8B8065780
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nikoloz Chkhartishvili
@ast
Nikoloz Chkhartishvili
@en
Nikoloz Chkhartishvili
@es
Nikoloz Chkhartishvili
@nl
type
label
Nikoloz Chkhartishvili
@ast
Nikoloz Chkhartishvili
@en
Nikoloz Chkhartishvili
@es
Nikoloz Chkhartishvili
@nl
prefLabel
Nikoloz Chkhartishvili
@ast
Nikoloz Chkhartishvili
@en
Nikoloz Chkhartishvili
@es
Nikoloz Chkhartishvili
@nl
P106
P1153
25227423400
P21
P31
P496
0000-0002-1309-825X